BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 27531238)

  • 1. A phase I/II clinical trial for the hybrid of intracavitary and interstitial brachytherapy for locally advanced cervical cancer.
    Murakami N; Kato S; Nakano T; Uno T; Yamanaka T; Sakurai H; Yoshimura R; Hiratsuka J; Kuroda Y; Yoshio K; Itami J
    BMC Cancer; 2016 Aug; 16():640. PubMed ID: 27531238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large volume was associated with increased risk of acute non-hematologic adverse events in the hybrid of intracavitary and interstitial brachytherapy for locally advanced uterine cervical cancer: preliminary results of prospective phase I/II clinical trial.
    Murakami N; Watanabe M; Uno T; Sekii S; Tsujino K; Kasamatsu T; Machitori Y; Aoshika T; Kato S; Hirowatari H; Kaneyasu Y; Nakagawa T; Ikushima H; Ando K; Murata M; Yoshida K; Yoshioka H; Murata K; Ohno T; Okonogi N; Saito A; Ichikawa M; Okuda T; Tsuchida K; Sakurai H; Yoshimura R; Yoshioka Y; Yorozu A; Okamoto H; Inaba K; Kato T; Igaki H; Itami J
    Jpn J Clin Oncol; 2022 Aug; 52(8):859-868. PubMed ID: 35470390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II prospective clinical trial for the hybrid of intracavitary and interstitial brachytherapy for locally advanced uterine cervical cancer.
    Murakami N; Watanabe M; Uno T; Sekii S; Tsujino K; Kasamatsu T; Machitori Y; Aoshika T; Kato S; Hirowatari H; Kaneyasu Y; Nakagawa T; Ikushima H; Ando K; Murata M; Yoshida K; Yoshioka H; Murata K; Ohno T; Okonogi N; Saito AI; Ichikawa M; Okuda T; Tsuchida K; Sakurai H; Yoshimura R; Yoshioka Y; Yorozu A; Kunitake N; Okamoto H; Inaba K; Kato T; Igaki H; Itami J
    J Gynecol Oncol; 2023 May; 34(3):e24. PubMed ID: 36603849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule.
    Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K;
    Gynecol Oncol; 2012 Aug; 126(2):211-6. PubMed ID: 22555110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Asian multi-national multi-institutional retrospective study comparing intracavitary versus the hybrid of intracavitary and interstitial brachytherapy for locally advanced uterine cervical carcinoma.
    Murakami N; Ando K; Murata M; Murata K; Ohno T; Aoshika T; Kato S; Okonogi N; Saito AI; Kim JY; Yoshioka Y; Sekii S; Tsujino K; Lowanichkiattikul C; Pattaranutaporn P; Kaneyasu Y; Nakagawa T; Watanabe M; Uno T; Umezawa R; Jingu K; Kanemoto A; Wakatsuki M; Shirai K; Igaki H; Itami J
    J Radiat Res; 2022 May; 63(3):412-427. PubMed ID: 35446962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Treatment Time on Chemoradiotherapy in Locally Advanced Cervical Carcinoma.
    Pathy S; Kumar L; Pandey RM; Upadhyay A; Roy S; Dadhwal V; Madan R; Chander S
    Asian Pac J Cancer Prev; 2015; 16(12):5075-9. PubMed ID: 26163644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined pretreatment with
    Ji S; Hu Q; Zhu J; Chen J; Chen Q; Liu Z; Shen C; Yang R; Sun H; Wu J; Gu K
    Trials; 2018 Aug; 19(1):416. PubMed ID: 30075736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-institutional phase II clinical study of concurrent chemoradiotherapy for locally advanced cervical cancer in East and Southeast Asia.
    Kato S; Ohno T; Thephamongkhol K; Chansilpa Y; Yuxing Y; Devi CR; Bustam AZ; Calaguas MJ; de los Reyes RH; Cho CK; Dung TA; Supriana N; Mizuno H; Nakano T; Tsujii H
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):751-7. PubMed ID: 19836154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent chemoradiotherapy using high-dose-rate intracavitary brachytherapy for uterine cervical cancer.
    Toita T; Moromizato H; Ogawa K; Kakinohana Y; Maehama T; Kanazawa K; Murayama S
    Gynecol Oncol; 2005 Mar; 96(3):665-70. PubMed ID: 15721409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized Controlled Trial Comparing Clinical Outcomes and Toxicity of Lobaplatin- Versus Cisplatin-Based Concurrent Chemotherapy Plus Radiotherapy and High-Dose-Rate Brachytherapy for FIGO Stage II and III Cervical Cancer.
    Wang JQ; Wang T; Shi F; Yang YY; Su J; Chai YL; Liu Z
    Asian Pac J Cancer Prev; 2015; 16(14):5957-61. PubMed ID: 26320479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective multi-institutional study of definitive radiotherapy with high-dose-rate intracavitary brachytherapy in patients with nonbulky (<4-cm) stage I and II uterine cervical cancer (JAROG0401/JROSG04-2).
    Toita T; Kato S; Niibe Y; Ohno T; Kazumoto T; Kodaira T; Kataoka M; Shikama N; Kenjo M; Tokumaru S; Yamauchi C; Suzuki O; Sakurai H; Numasaki H; Teshima T; Oguchi M; Kagami Y; Nakano T; Hiraoka M; Mitsuhashi N
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):e49-56. PubMed ID: 21470794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility study of toxicity outcomes using GEC-ESTRO contouring guidelines on CT based instead of MRI-based planning in locally advanced cervical cancer patients.
    Koh V; Choo BA; Lee KM; Tan TH; Low JH; Ng SY; Ilancheran A; Shen L; Tang J
    Brachytherapy; 2017; 16(1):126-132. PubMed ID: 27816539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Definitive radiotherapy consisting of whole pelvic radiotherapy with no central shielding and CT-based intracavitary brachytherapy for cervical cancer: feasibility, toxicity, and oncologic outcomes in Japanese patients.
    Kusada T; Toita T; Ariga T; Kudaka W; Maemoto H; Makino W; Ishikawa K; Heianna J; Nagai Y; Aoki Y; Murayama S
    Int J Clin Oncol; 2020 Nov; 25(11):1977-1984. PubMed ID: 32852648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study.
    Chung YL; Jian JJ; Cheng SH; Hsieh CI; Tan TD; Chang HJ; Hung CF; Horng CF; Soong T; Tsou MH
    Gynecol Oncol; 2005 Apr; 97(1):126-35. PubMed ID: 15790448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-institutional Observational Study of Prophylactic Extended-Field Concurrent Chemoradiation Therapy Using Weekly Cisplatin for Patients With Pelvic Node-Positive Cervical Cancer in East and Southeast Asia.
    Wakatsuki M; Kato S; Ohno T; Banu PA; Hoang NC; Yadamsuren E; Supriana N; Cao J; Devi CRB; Calaguas MJ; Chansilpa Y; Cho CK; Adylkhanov T; Okonogi N; Nakano T; Tsujii H
    Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):183-189. PubMed ID: 31125594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG1066).
    Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K;
    Int J Gynecol Cancer; 2012 Oct; 22(8):1420-6. PubMed ID: 22932262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant Chemoradiotherapy With Image-guided Pulsed Dose Rate Brachytherapy as a Definitive Treatment Modality for Early-stage Cervical Cancer.
    Refaat T; Castelain B; Small W; Elsaid A; Lotfy N; Lartigau E; Nickers P
    Am J Clin Oncol; 2015 Jun; 38(3):289-93. PubMed ID: 23799285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer.
    Pötter R; Dimopoulos J; Georg P; Lang S; Waldhäusl C; Wachter-Gerstner N; Weitmann H; Reinthaller A; Knocke TH; Wachter S; Kirisits C
    Radiother Oncol; 2007 May; 83(2):148-55. PubMed ID: 17531904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes of concomitant chemoradiotherapy incorporating high-dose-rate brachytherapy to treat locally advanced cervical cancer.
    Lee HJ; Kim YS; Shin SS; Nam JH; Kim YT; Han S; Choi EK
    Tumori; 2012; 98(5):615-21. PubMed ID: 23235757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose, prophylactic, extended-field, intensity-modulated radiotherapy plus concurrent weekly cisplatin for patients with stage IB2-IIIB cervical cancer, positive pelvic lymph nodes, and negative para-aortic lymph nodes.
    Liang JA; Chen SW; Hung YC; Yeh LS; Chang WC; Lin WC; Chang YY
    Int J Gynecol Cancer; 2014 Jun; 24(5):901-7. PubMed ID: 23975081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.